HDR, Prostate Cancer
Conditions
Keywords
Brachytherapy, Prostate Cancer, High-Dose-Rate (HDR)
Brief summary
The purpose of this study is to learn more about what effects the use of high-dose-rate (HDR) brachytherapy on prostate cancer recurrence, seen by AXUMIN PET scan, has on prostate cancer.
Detailed description
In this study the investigator would like to better understand the use of high-dose rate (HDR) brachytherapy to target only recurrent prostate cancer that can be seen by AXUMIN PET scan. The use of HDR brachytherapy for prostate cancer is not new, but it is a more recent advancement to use it to treat only what can be seen instead of the whole prostate.
Interventions
PROCEDUREHigh-Dose-Rate Brachytherapy
High-Dose-Rate Brachytherapy Targeting only to AXUMIN PET Visible Lesion
Sponsors
University of Rochester
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
History of histologically confirmed, clinically localized adenocarcinoma of the prostate treated with external beam radiation, brachytherapy, or combination of external beam radiation and brachytherapy, with curative intent completed at least 24 months ago F-18 fluciclovine (AXUMIN) PET scan within 90 days prior to registration demonstrating recurrent lesion within the prostate gland Biopsy confirmation of disease recurrence within the prostate gland Age ≥ 18 KPS ≥ 70% Suitable candidate for brachytherapy based on established criteria IPSS score \<16 No pelvic arch interference No Rectal fistula/fissure Fit for general or spinal anesthesia No history of urethral stricture Ability to understand, and willingness to sign the written informed consent
Exclusion criteria
Evidence of metastatic or nodal disease outside of the prostate gland on AXUMIN PET scan within 90 days prior to enrollment Patient unable to have MRI Patients with neuroendocrine or small cell carcinoma of the prostate TURP within 6 months prior to enrollment History of Crohn's disease, ulcerative colitis, or known radiation proctitis Inability to understand spoken and written English
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with prostate-specific antigen (PSA) levels rising of 2ng/ml or above | 6 Months | Rate of prostate-specific antigen (PSA) failure after focal salvage HDR in the setting of prostate only recurrence after primary non-surgical treatment, defined as a PSA rise of 2 ng/ml or more above the nadir at 6 months |
| Incidence of Treatment-Related Adverse Events [Safety and Tolerability] | 6 Months | Measured by adverse event severity and quantity |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival | 6 Months | Measure of time from study enrollment until progression. |
Countries
United States
Outcome results
None listed